Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in Brain
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus (AAV) vectors effectively transfer and express foreign genes in the brain. The transferred genes, however, are selectively expressed in neurons, and the cause of this specificity is not understood. To address this question, wild-type AAV-2 capsids were covalently labeled with the fluorophore, Cy3, and infused into the inferior colliculus or the hippocampus. Using antibodies to identify neurons (NeuN), astrocytes (GFAP), or oligodendrocytes (OX-42), clear neuron-specific uptake of the virus was observed as early as 6 min after the start of the infusion. By 30 min postinfusion, AAV particles were present in the nucleus of neurons, yet in both the inferior colliculus and hippocampus, a subset of neurons did not take up the virus particles. No AAV particles were found in astrocytes 1.5 min or 24 hr after virus infusion. Interestingly, 1 hr postinfusion, no AAV particles were found in microglia, yet by 24 hr postinfusion, a punctate pattern of AAV particles was found in microglia. To test whether virus uptake correlated with vector-transduced cells, an rAAV-CMV-GFP virus was infused. By 3 days postinfusion, GFP was localized to neuronal populations with no expression in astrocytes or microglia, similar to that of fluorescent virus uptake. These findings demonstrate that in brain, AAV particles rapidly bind and enter primarily neurons with a pattern similar to that of in vivo vector transduction. In addition, these studies indicate that viral binding and uptake, independent of promoter tropism, can explain the specificity of AAV brain transduction. Thus, this first description of AAV kinetic disposition in vivo should facilitate targeted application of this vector for human brain gene therapy. To investigate in vivo observations of selective neural gene expression after AAV infection, wild-type AAV-2 capsids were covalently labeled with a fluorophore and infused into the inferior colliculus or the hippocampus. Using antibodies to identify neurons, astrocytes, or oligodendrocytes, clear neuron-specific uptake of the virus was observed as early as 6 min after the start of the infusion, and by 30 min AAV particles were clearly present in the nucleus of neurons. In both the inferior colliculus and hippocampus, however, a subset of neurons did not take up the virus particles, and no AAV particles were found in astrocytes. Three days after AAV-CMV-GFP infusion, gene product was localized to neuronal populations similar to that of fluorescent virus uptake, but not in astrocytes or microglia. Thus, the binding and uptake of AAV provide a promoter-independent explanation for the observed in vivo neural tropism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Self-citationFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“Also, given the number of factors that can alter A AV vector expres sion (Alexander et al, 1994; Russell et al, 1995; Ferrari et al, 1996; Fisher et al, 1996), it is possible that vector genomes could be present in cells that lack the ability to initiate vector-derived gene expression.”
Self-citationSamulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
Self-citationFisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
McCown, T. J., Xiao, X., Li, J., Breese, G. R., & Jude Samulski, R. (1996) · Brain Research · doi:10.1016/0006-8993(95)01488-8 · Cited by 450
Self-citationPeel, A., Zolotukhin, S., Schrimsher, G., Muzyczka, N., & Reier, P. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300358 · Cited by 289
Alexander, I. E., Russell, D. W., & Miller, A. D. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8282-8287.1994 · Cited by 222
DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.
Russell, D. W., Alexander, I. E., & Miller, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5719 · Cited by 218
Mato, M., Ookawara, S., Sakamoto, A., Aikawa, E., Ogawa, T., Mitsuhashi, U., Masuzawa, T., Suzuki, H., Honda, M., Yazaki, Y., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3269 · Cited by 187 · cited 1×
“Further support for this conclusion arises from the observations that both mi croglia and capiUary endothelial ceUs in the brain contain scav enger receptors that mediate endocytosis and degradation (Mato et al, 1996; Grewal et al, 1997).”
Cited by
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Self-citationDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532
Self-citationKirik, D., Rosenblad, C., Björklund, A., & Mandel, R. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04686.2000 · Cited by 428
Cearley, C. N., & Wolfe, J. H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.015 · Cited by 409
Bielsky, I. F., Hu, S.-B., Ren, X., Terwilliger, E. F., & Young, L. J. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.031 · Cited by 367
Theodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367
Björklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., & Mandel, R. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02915-2 · Cited by 346
Viral vectors for gene delivery to the nervous system
Davidson, B. L., & Breakefield, X. O. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1104 · Cited by 321
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Pitkow, L. J., Sharer, C. A., Ren, X., Insel, T. R., Terwilliger, E. F., & Young, L. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07392.2001 · Cited by 295
“Transduction by AAV-2 vectors into the brain is primarily confined to neurons (Bartlett et al., 1998), but the NSE promoter further restricts expression to neurons (Peel et al.”
BackgroundCRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections
van Diemen, F. R., Kruse, E. M., Hooykaas, M. J. G., Bruggeling, C. E., Schürch, A. C., van Ham, P. M., Imhof, S. M., Nijhuis, M., Wiertz, E. J. H. J., & Lebbink, R. J. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005701 · Cited by 290
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Self-citationFischer, D., He, Z., & Benowitz, L. I. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5119-03.2004 · Cited by 276
Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 275
Sanlioglu, S., Benson, P. K., Yang, J., Atkinson, E. M., Reynolds, T., & Engelhardt, J. F. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9184-9196.2000 · Cited by 269
Intracellular transport of recombinant adeno-associated virus vectors
Nonnenmacher, M., & Weber, T. (2012) · Gene Therapy · doi:10.1038/gt.2012.6 · Cited by 258
Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255
“Even with strong glial promoters, cellular transduction and gene expression with AAV-2 occurs predominantly in neurons (Bartlett et al ., 1998; Xu et al ., 2001), though oligo-dendrocytes, astrocytes, or microglia may be transduced to a limited extent.”
Intravitreal injection of AAV2 transduces macaque inner retina
Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, R., Visel, M., Stone, D., Libby, R. T., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6250 · Cited by 212
Klimczak, R. R., Koerber, J. T., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007467 · Cited by 210
“encodes three structural proteins (VP1–3) that assemble into a 60-mer capsid shell. This viral capsid mediates the ability of AAV vectors to overcome many of the biological barriers of viral transduction–including cell surface receptor binding, endocytosis, intracellular trafficking, and unpackaging in the nucleus”
BackgroundPaterna, J.-C., Moccetti, T., Mura, A., Feldon, J., & Büeler, H. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301221 · Cited by 189
Passini, M. A., & Wolfe, J. H. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12382-12392.2001 · Cited by 185
“The carbocyanine dye CY3 was covalently linked to the protein coat of AAV2-H H virions according to the CyDye-FluoroLink labeling kit protocol (Amersham-Life Sciences) (5, 32).”
Molecular evolution of adeno-associated virus for enhanced glial gene delivery
Koerber, J. T., Klimczak, R., Jang, J.-H., Dalkara, D., Flannery, J. G., & Schaffer, D. V. (2009) · Molecular Therapy · doi:10.1038/mt.2009.184 · Cited by 181
Xu, R., Janson, C., Mastakov, M., Lawlor, P., Young, D., Mouravlev, A., Fitzsimons, H., Choi, K.-L., Ma, H., Dragunow, M., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301529 · Cited by 174
Lawlor, P. A., Bland, R. J., Mouravlev, A., Young, D., & During, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.170 · Cited by 161
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
“10 all exhibit strong neuronal tropism, as gene expression rarely colocalizes with markers of astrocytes or oligodendrocytes [ 18 – 21 ].”
BackgroundTargeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
Samaranch, L., Sebastian, W. S., Kells, A. P., Salegio, E. A., Heller, G., Bringas, J. R., Pivirotto, P., DeArmond, S., Forsayeth, J., & Bankiewicz, K. S. (2014) · Molecular Therapy · doi:10.1038/mt.2013.266 · Cited by 142
Reversal of Depressed Behaviors in Mice by p11 Gene Therapy in the Nucleus Accumbens
Alexander, B., Warner-Schmidt, J., Eriksson, T. M., Tamminga, C., Arango-Lievano, M., Ghose, S., Vernov, M., Stavarache, M., Musatov, S., Flajolet, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001079 · Cited by 140
“Furthermore, because AAV2 is highly selective for neurons, these results indicate that p11 loss within neurons of NAcc induces depression-like behaviors (10, 21).”
Harvey, A. R., Kamphuis, W., Eggers, R., Symons, N. A., Blits, B., Niclou, S., Boer, G. J., & Verhaagen, J. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1168 · Cited by 114
Nieuwenhuis, B., Haenzi, B., Hilton, S., Carnicer-Lombarte, A., Hobo, B., Verhaagen, J., & Fawcett, J. W. (2021) · Gene Therapy · doi:10.1038/s41434-020-0169-1 · Cited by 114
Recombinant Adeno-Associated Viral Vectors in the Nervous System
Burger, C., Nash, K., & Mandel, R. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.781 · Cited by 110
Adeno‐associated virus vectors and hematology
Russell, D. W., & Kay, M. A. (1999) · Blood · doi:10.1182/blood.v94.3.864.415k34_864_874 · Cited by 104
Dodiya, H. B., Bjorklund, T., Stansell III, J., Mandel, R. J., Kirik, D., & Kordower, J. H. (2010) · Molecular Therapy · doi:10.1038/mt.2009.216 · Cited by 86
Merienne, N., Douce, J. L., Faivre, E., Déglon, N., & Bonvento, G. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00106 · Cited by 58
“Indeed, the injection of AAV2 into adult rodent brains was associated with neuronal transgene expression when using ubiquitous promoters (Bartlett et al., 1998; Mandel et al., 1999; Bjorklund et al., 2000).”
BackgroundDestination Brain: the Past, Present, and Future of Therapeutic Gene Delivery
Joshi, C. R., Labhasetwar, V., & Ghorpade, A. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9724-3 · Cited by 55
“However, in a later study, cytomegalovirus (CMV) or human (h) synapsin (Syn) promoterdriven AAV2 specifically transduced astrocytes and neurons, respectively (Kügler et al. 2003).”
InfluentialHarding, T. C., Dickinson, P. J., Roberts, B. N., Yendluri, S., Gonzalez-Edick, M., Lecouteur, R. A., & Jooss, K. U. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.807 · Cited by 45
“With serotype 2 vectors, (cid:8) 90% of GFP-positive cells costained with Nissl as previously reported (Bartlett et al ., 1998; R. Xu et al ., 2001; Burger et al ., 2004).”
Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0017-8 · Cited by 37
Quantitative 3D Tracing of Gene-delivery Viral Vectors in Human Cells and Animal Tissues
Xiao, P.-J., Li, C., Neumann, A., & Samulski, R. J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.250 · Cited by 33
Self-citationA new method to measure autophagy flux in the nervous system
Matus, S., Valenzuela, V., & Hetz, C. (2014) · Autophagy · doi:10.4161/auto.28434 · Cited by 29
Zhou, L., Wang, Y., Xu, Y., Zhang, Y., & Zhu, C. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03232-2 · Cited by 26
“Intracranial injection of 9E10 vector genome (vg) wild type AAV2 labeled with Cy3 dye and 2.5E10 vg rAAV2 with a CMV promotor demonstrated robust transduction in neurons but negligible transduction in microglia within the hippocampus and the inferior colliculus of the rat brain [39].”
Backgroundde Oliveira, A. P., & Fraefel, C. (2010) · The Open Virology Journal · doi:10.2174/1874357901004030109 · Cited by 3
Metadata
- Authors
- Bartlett, J. S., Samulski, R. J., & McCown, T. J.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1998-05-20
- Volume
- 9
- Issue
- 8
- Pages
- 1181-1186
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1972747973
- Cited by
- 301
- References
- 16
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.